Education
About Us
Working with TipRanks
Follow Us
TransCode Therapeutics (RNAZ)
NASDAQ:RNAZ
RNAZ Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.89 - $66.33
Previous CloseN/A
Volume52.57K
Average Volume (3M)3.40M
Market Cap
$1.38M
Enterprise Value$6.66M
Total Cash (Recent Filing)$204.47K
Total Debt (Recent Filing)$927.81K
Price to Earnings (P/E)―
Beta2.87
Next Earnings
Mar 28, 2025EPS Estimate
-105.93Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-265.83
Shares Outstanding696,249
10 Day Avg. Volume461,120
30 Day Avg. Volume3,403,660
Standard Deviation0.52
R-Squared0.00889
Alpha-0.09
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.10
P/FCF Ratio0.00
Enterprise Value/Market Cap4.83
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-12.89
Enterprise Value/Ebitda-0.47
Forecast
1Y Price Target
$20.00Price Target Upside910.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe study has been enrolling patients rapidly with nine patients having been dosed with TTX-MC138 to date since the study initiated, which for a novel MoA and novel target, is quick.
Financial SupportAn NIH grant of $2M was awarded to the company to assist in funding the trial.
Bears Say
Investor SentimentInvestors may be disappointed with not seeing initial responses.
---
Ownership Overview
8.49%
Insiders
5.43%
Mutual Funds
― Other Institutional Investors
91.51% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
RNAZ FAQ
What was TransCode Therapeutics’s price range in the past 12 months?
TransCode Therapeutics lowest stock price was $1.89 and its highest was $66.33 in the past 12 months.
What is TransCode Therapeutics’s market cap?
TransCode Therapeutics’s market cap is $1.38M.
When is TransCode Therapeutics’s upcoming earnings report date?
TransCode Therapeutics’s upcoming earnings report date is Mar 28, 2025 which is in 25 days.
How were TransCode Therapeutics’s earnings last quarter?
TransCode Therapeutics released its earnings results on Nov 11, 2024. The company reported -$5.28 earnings per share for the quarter, beating the consensus estimate of -$16.17 by $10.89.
Is TransCode Therapeutics overvalued?
According to Wall Street analysts TransCode Therapeutics’s price is currently Undervalued.
Does TransCode Therapeutics pay dividends?
TransCode Therapeutics does not currently pay dividends.
What is TransCode Therapeutics’s EPS estimate?
TransCode Therapeutics’s EPS estimate is -105.93.
How many shares outstanding does TransCode Therapeutics have?
TransCode Therapeutics has 696,249 shares outstanding.
What happened to TransCode Therapeutics’s price movement after its last earnings report?
TransCode Therapeutics reported an EPS of -$5.28 in its last earnings report, beating expectations of -$16.17. Following the earnings report the stock price went down -12.067%.
Which hedge fund is a major shareholder of TransCode Therapeutics?
Currently, no hedge funds are holding shares in RNAZ
---
Company Description
TransCode Therapeutics
TransCode Therapeutics Inc is an RNA oncology company. It is created to defeat the cancer through the intelligent design and effective delivery of RNA therapeutics. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others.
---
RNAZ Stock 12 Month Forecast
Average Price Target
$20.00
▲(910.10% Upside)
Technical Analysis
Alnylam Pharma
―
Arrowhead Pharmaceuticals
―
Ionis Pharmaceuticals
―
Sarepta Therapeutics
―
Moderna
―
Best Analysts Covering RNAZ
1 Year
1 Year Success Rate
0/16 ratings generated profit
1 Year Average Return
-88.11%
reiterated a buy rating 25 days ago
Copying Emily Bodnar's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -88.11% per trade.
---